Phase 3 data show the oral BTK inhibitor reduced annualized relapse rate by 35.2% and 31.2% vs teriflunomide, with no liver safety signal or Hy's Law cases.
|Videos|July 22, 2021
Evolving Rehabilitation Strategies for Multiple Sclerosis
Ahmed Obeidat, MD, PhD; Francois Bethoux, MD; and Nicholas C. Ketchum, MD, discuss recent advancements and future directions in rehabilitation strategies for multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Nicholas C. Ketchum, MD
Residency Program Director, Department of Physical Medicine and Rehabilitation, Medical College of Wisconsin - Francois Bethoux, MD
Director, Rehabilitation Services, Mellen Center for MS Treatment and Research, Cleveland Clinic
Key Learning Objectives
- Gait and ambulation in multiple sclerosis
- Spasticity and its management in multiple sclerosis
- Technology and rehabilitation in multiple sclerosis
- Traditional versus nontraditional approaches of rehabilitation in multiple sclerosis
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
A phase 2 trial found liposomal mitoxantrone hydrochloride had an acceptable safety profile and a potential trend toward fewer relapses in neuromyelitis optica spectrum disorder.
The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.
Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.
Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in progressive MS.
Early phase 1 data in 3 patients suggest CTA313, an allogeneic CD19/BCMA CAR-T, may stabilize disability with a manageable safety profile in progressive MS.
One-year data from the phase 3 AQUARELLE study found that divozilimab, an anti-CD20 antibody, reduced relapse risk in patients with neuromyelitis optica spectrum disorder.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS
2
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
3
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
4
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
5